Glooko makes its management app free to any person with diabetes

Hand holding phone with Glooko app against background of a garden
Glooko’s free app will include all the previously available features, including helping users track their glucose levels and spot trends. (Glooko)

Glooko has made its mobile app free for any person with diabetes, ditching the subscription fees that had applied to users who were not sponsored through their provider, health plan or employer.

The move comes on the heels of announcements promising that the 2015 Fierce 15 company’s product will be compatible with platforms such as Senseonics’ implantable, long-term continuous glucose monitoring hardware, as well as the upcoming connected insulin pens from Novo Nordisk.

While one-time hardware costs may still apply, Glooko’s free version will include all the previously available features, including helping users track their glucose levels and spot trends connected to synced food, exercise and medication data. It also allows healthcare providers to check in and monitor progress remotely.

Conference

Save 25% on The Digital MedTech Conference in San Francisco

Register with code SPRING25 and save 25% on the Digital MedTech Conference May 22-23 in San Francisco. Participate in interactive discussions on telehealth, data privacy, block chain, and more including a special fireside chat on AI featuring FDA's Medical Officer of Digital Health.

“I am thrilled we are removing the subscription fee for users of the mobile app—this will allow anyone who wants to use Glooko for self-management to be able to do so,” CEO Russ Johannesson said in a statement, adding that it will also allow providers to monitor larger patient populations. “Diabetes is a very complicated, data-intensive condition; more frequent support for patients is critical in helping them better manage their diabetes.”

RELATED: Novo Nordisk to make its digital insulin pens compatible with Abbott, Glooko and more

According to the company, its remote monitoring programs have been shown to help improve average blood glucose outcomes by 12%, after three months of patient coaching, and helped reduce hyperglycemia events by 15%.

For users of Senseonics’ 90-day Eversense CGM system—launched in August of last year—logged blood glucose, insulin, food intake and other data will be shared with Glooko after connecting their Eversense account in the cloud, the company said in a statement.  

RELATED: Roche, Senseonics extend diabetes monitor distribution deal to BRIC countries

“Glooko has a large database of millions of users who are now able to see a clearer picture of their glucose profiles by integrating Eversense CGM data,” said Senseonics President and CEO Tim Goodnow. “With personalized medicine at the forefront of healthcare, data integration between Eversense CGM and Glooko helps provide customized data for users as well as healthcare providers.”

Suggested Articles

Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.

The FBI has launched its own probe into some of the world’s largest medtech companies, stemming from a Brazilian corruption case, Reuters reports.

AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.